Rare Presentation of a Rare Tumor: Histiocytic Sarcoma

Reddivari, Anil Kumar Reddy; Mehta, Parth; Janapala, Usha Sree

doi:10.7759/cureus.7770

Cited by 2 publications

(2 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dopamine (D2) receptor antagonists such as metoclopramide have been shown to have beneficial effects on Gp-like symptoms and is currently the only FDA-approved drug for Gp. 30 Its efficacy is supported by a low quality of evidence, and use is limited due to the risk of side effect, including tardive dyskinesia. 31 Antiemetics, including 5HT-3 receptor antagonists and neurokinin antagonists, may be helpful in cases where nausea and vomiting are the predominant symptoms.…”

Section: Discussionmentioning

confidence: 99%

Baseline Characteristics and Predictive Factors of Intravenous Immunoglobulin Response in Drug and Device Refractory Gastroparesis Symptoms

Gala

Stocker²,

Tu³

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Introduction: Intravenous immunoglobulin (IVIG) has been shown in a small pilot series to be helpful for some patients with gastroparesis that is refractory to drugs, devices, and surgical therapies. Many but not all patients have serologic neuromuscular markers. We hypothesize that those patients with serologic markers and/or longer duration of therapy would have better responses to IVIG. Materials and Methods: We studied 47 patients with a diagnosis of gastroparesis and gastroparesis-like syndrome that had all failed previous therapies including available and investigational drugs, devices, and/or pyloric therapies. Patients had a standardized 12-week course of IVIG, dosed as 400 mg/kg per week intravenously. Symptom assessment was done with Food and Drug Administration (FDA) compliant traditional patient-reported outcomes. Success to IVIG was defined as 20% or greater reduction in average symptom scores from baseline to the latest evaluation. Results: Fourteen patients (30%) had a response, and 33 (70%) had no response per our definition. Patients responding had a higher glutamic acid decarboxylase 65 positivity (64% vs. 30%, P=0.049, missing=3) and longer duration of therapy (>12 wk/continuous: 86% vs. 48%, P=0.09). Conclusions: In this moderately sized open-label series of refractory patients with gastroparesis symptoms treated with IVIG, 30% of patients responded. While serologic markers and extended therapies show a trend to greater response, neither was statistically significant, except for glutamic acid decarboxylase 65 which showed a higher positivity rate in responders. We conclude that a clinical trial of IVIG may be warranted in severely refractory patients with gastroparesis symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Baseline Characteristics and Predictive Factors of Intravenous Immunoglobulin Response in Drug and Device Refractory Gastroparesis Symptoms

Gala

Stocker²,

Tu³

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Considering these symptoms' duration, severity, and impact on the patient's quality of life is crucial. Additionally, assessing the presence of comorbidities, such as diabetes and cardiology conditions, helps establish the context for developing gastroparesis [11].…”

Section: Diagnosis Of Gastroparesis In Patients With Diabetes and Car...mentioning

confidence: 99%

A Comprehensive Literature Review on the Relationships and Management of Gastroparesis

Okobi,

Sike,

Nwatamole

et al. 2023

International Journal of Scientific Advances

View full text Add to dashboard Cite

This literature review aims to explore the intricate interplay between diabetes, cardiology, and gastroparesis. Diabetes is a chronic metabolic disorder that significantly affects cardiovascular health, and its association with gastroparesis further complicates patient management. The review critically analyzes recent research articles, clinical studies, and guidelines to elucidate the pathophysiology, epidemiology, diagnostic approaches, and therapeutic interventions for patients with diabetes, cardiology conditions, and concurrent gastroparesis. The findings highlight the impact of gastroparesis on glycemic control, cardiac function, and overall quality of life, emphasizing the need for a multidisciplinary approach to patient care. Additionally, the review explores potential mechanisms linking diabetes, cardiac dysfunction, and gastroparesis, such as autonomic neuropathy, inflammatory pathways, and impaired gut-brain axis communication. Finally, the literature review discusses current treatment strategies, including lifestyle modifications, pharmacological therapies, and novel interventions, while also addressing challenges and gaps in the existing literature. This comprehensive analysis provides clinicians, researchers, and healthcare professionals valuable insights to enhance their understanding of the complex relationship between diabetes, cardiology, and gastroparesis, ultimately promoting optimal patient care and management.

show abstract

Rare Presentation of a Rare Tumor: Histiocytic Sarcoma

Cited by 2 publications

References 5 publications

Baseline Characteristics and Predictive Factors of Intravenous Immunoglobulin Response in Drug and Device Refractory Gastroparesis Symptoms

Baseline Characteristics and Predictive Factors of Intravenous Immunoglobulin Response in Drug and Device Refractory Gastroparesis Symptoms

A Comprehensive Literature Review on the Relationships and Management of Gastroparesis

Contact Info

Product

Resources

About